Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Proficient Cultivating Devices for a Lovely and Useful Nursery in 2024 - 2UK clothing inflation climbs as Middle East turmoil threatens wider price rises
- 3Carrefour becomes first European retailer to offer shopping on ChatGPT
- 4Find the Excellence of Old style Expressive dance: Encountering the Effortlessness and Polish of Dance
- 5Shredded cheese recall: Multiple brands sold at Aldi, Target and Walmart affected over potential metal fragment contamination
- How to disinfect if the stomach bug hits your home
- Figure out What Experience Level Means for Medical caretaker Compensation Dealings
- Vietnam rethinks its flood strategy as climate change drives storms and devastation
- Electric discovery on Mars! Scientists find tiny lightning bolts coming from Red Planet dust clouds
- 'We were genuinely astonished': This moss survived 9 months outside the International Space Station and could still grow on Earth
- 6 U.S. States for Climbing
- Australia Cracks Down on Gambling Ads as Prediction Markets Like Polymarket Remain Blocked
- UK consumer confidence plunges amid escalating Iran conflict
- Middle East hotels hit pandemic-era lows amid Iran war
